Biotechnology, Venture Capital, Oncology · medium ·
DNA Vaccine Investment Faces a Delivery Solution Shortage
Investment in DNA vaccine platforms is becoming increasingly selective, focusing on companies and projects that can demonstrate de-risked delivery solutions and strong T-cell-inducing indications. This creates a critical shortage of validated delivery technologies, making them a key bottleneck for attracting capital.
Part of the Private Equity & M&A Opportunity Outlook, Korim's monthly analysis of emerging opportunities in this sector.
Part of the Healthcare & Life Sciences Opportunity Outlook, Korim's monthly analysis of emerging opportunities in this sector.
Part of the Technology Opportunity Outlook, Korim's monthly analysis of emerging opportunities in this sector.